Quick Answer
Celularity Inc reported Research And Development Expense of $17.39 million for the year ending 2024.
- Celularity Inc showed a decrease of -42.9% in Research And Development Expense from 2023 to 2024.
- This data is from Celularity Inc's annual report (Form 10-K), filed with the SEC on May 8, 2025.
- XBRL data for this metric is available from 2020 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $11.22 million | Q1 2021: $16.99 million | Q2 2021: $22.91 million | Q3 2021: $23.77 million | Q1 2022: $21.67 million | Q2 2022: $25.35 million | Q3 2022: $20.35 million | Q1 2023: $16.95 million | Q2 2023: $8.60 million | Q3 2023: $5.18 million | Q1 2024: $5.84 million | Q2 2024: $3.80 million | Q3 2024: $3.92 million | Q1 2025: $3.73 million | Q2 2025: $3.35 million | Q3 2025: $4.60 million.
- Over the full 5 years of available data (2020 to 2024), Celularity Inc's Research And Development Expense has declined by 67.0%.
- Historical annual values: Fiscal year 2024: $17.39 million | Fiscal year 2023: $30.47 million | Fiscal year 2022: $78.36 million | Fiscal year 2021: $88.35 million | Fiscal year 2020: $52.71 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: